Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US90466Y1038
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01163JG34
UNCY
Unicycive Therapeutics, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Unicycive Therapeutics, Inc.
ISIN
US90466Y1038
TICKER
UNCY
MIC
XNAS
REUTERS
UNCY.OQ
BLOOMBERG
UNCY US
Do., 02.07.2026       Unicycive Therapeutics
US90466Y1038

Boston, Massachusetts--(Newsfile Corp. - July 2, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more de...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 02.07.2026       Unicycive Therapeutics
US90466Y1038

The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT TH...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 30.06.2026       Unicycive Therapeutics
US90466Y1038

-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission review --...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Unicycive Therapeutics
US90466Y1038

MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. ...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcar...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the c...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Unicycive Therapeutics
US90466Y1038

Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Unicycive...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.02.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emer...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 29.01.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (N...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (N...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 29.12.2025       Unicycive Therapeutics
US90466Y1038

New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 01.12.2025       Unicycive Therapeutics
US90466Y1038

Philadelphia, Pennsylvania--(Newsfile Corp. - December 1, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Unicycive Therapeutics, Inc. (...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 12.11.2025       Unicycive Therapeutics
US90466Y1038

-   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.10.2025       Unicycive Therapeutics
US90466Y1038

Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from pre-trial phosphate binder therapy Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Unicycive Therapeutics
US90466Y1038

Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.10.2025       Unicycive Therapeutics
US90466Y1038

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Unicycive is a clinical-stage biotechnology company. For more information, s...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 14.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Oct. 13, 2025 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Oct. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 a...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docke...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholde...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 11.10.2025       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholder...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docket...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholder...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 04.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the "Class Period"), of the important October 14, 2025 lead plaintiff deadl...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 03.10.2025       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 03.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docke...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 02.10.2025       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 an...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 02.10.2025       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 29.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Sharehold...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 28.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and dock...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFI...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Unicycive Therapeutics
US90466Y1038

The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of UNCY...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are en...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 24.09.2025       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 23.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beha...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 22.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are en...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFI...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.09.2025       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beh...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink